Not what I was expecting in terms of price or total $. But honestly I really didn't know what to expect. $10 million will hopefully be enough, in my opinion, to carry us through to the end of August. Between now and then, Resverlogix should cross several milestones (see below) based upon previous company communications and estimated timelines. They will also need to resolve the issue of paying/re-negotiating the $68.8 million loan by August 28, 2017.
- Continue BETonMACE through end of August
- Launch the Phase 2a Renal Trial (anticipated start date June 15)
- Launch the Fabry's disease trial (no disclosed start date)
- 4th DSMB report
- Futility analysis (assuming it occurs by end of August)
- Decision from FDA on inclusion in Phase 3 BETonMACE
- ESC 2017 meeting (at least three apabetalone abstracts)
- IND filing for second compound
- Launch of PNH orphan trial
- Several more publications
- Much needed and overdue corporate update webcast (hopefully before end of June) in addition to BIO International corporate update
